Across TCGA pan-cancer cohorts, RPL7AP9 RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated RPL7AP9 data layer.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RPL7AP9 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RPL7AP9 expression acts as an unfavorable survival marker, although some lineages such as SKCM and LIHC show a favorable association.
SKCM, READ, and LIHC are the cancer types where RPL7AP9 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.